Central poststroke pain and Wallenberg's lateral medullary infarction: Frequency, character, and determinants in 63 patients.
In PLoS ONE, 1996
... Corp.), substance P receptor (rabbit NK-1; 1∶7,500; Chemicon, Temecula, CA, USA), calcitonin gene-related peptide (guinea pig anti-CGRP; 1∶5,000; Peninsula Laboratories [now Bachem AG; Torrance, CA, USA]), ...
Challenges in developing drugs for primary headache.
Copenhagen, Denmark. In Prog Neurobiol, Feb 2016
The development of the triptan class of serotonin 5-HT1B/1D/1F receptor agonists has advanced our understanding of the neurobiology of migraine pain, which subsequently resulted in the development of calcitonin gene related peptide (CGRP) modulators that are now showing promise as acute and preventative anti-migraine agents.
Endomorphin Analog Analgesics with Reduced Abuse Liability, Respiratory Depression, Motor Impairment, Tolerance, and Glial Activation.
New Orleans, United States. In Neuropharmacology, Jan 2016
At doses providing equal or greater antinociception than morphine in the rat, the analogs showed reduced a) respiratory depression, b) impairment of motor coordination, c) tolerance and hyperalgesia, d) glial p38/CGRP/P2X7 receptor signaling, and e) reward/abuse potential in both conditioned place preference and self-administration tests.
Elucidating an Affective Pain Circuit that Creates a Threat Memory.
Seattle, United States. In Cell, Aug 2015
Here, we show that neurons expressing calcitonin gene-related peptide (CGRP) in the parabrachial nucleus are critical for relaying pain signals to the central nucleus of amygdala and that this pathway may transduce the affective motivational aspects of pain.
[Effect of alcohol on vascular function].
In Nihon Arukoru Yakubutsu Igakkai Zasshi, Jun 2015
Furthermore, acute ethanol ingestion can also potentiate and suppress calcitonin gene-related peptide (CGRP)-induced nerve-mediated relaxation.
New players in the preventive treatment of migraine.
Athens, Greece. In Bmc Med, 2014
Recently, three monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) ligand (LY2951742, ALD403 and TEV-48125) and one targeting the CGRP receptor (AMG 334) have completed phase 2 trials, and the results have been reported.